Table 2 Baseline characteristics of patients with prostate cancer based on mGPS categories
The modified Glasgow prognostic score (mGPS) | P-value | |||
|---|---|---|---|---|
mGPS = 0 | mGPS = 1 | mGPS = 2 | ||
Patients, n (%) | Patients, n (%) | Patients, n (%) | ||
Age at incidence (years) | ||||
Age < 65 | 88 (25.29) | 71 (21.78) | 7 (10.00) | 0.014 |
Age 65-74 | 127 (36.49) | 112 (34.36) | 22 (31.43) | |
Age ≥ 75 | 133 (38.22) | 143 (43.87) | 41 (58.57) | |
Gleason score | ||||
Gleason < 7 | 95 (27.30) | 67 (20.55) | 15 (21.43) | <0.001 |
Gleason = 7 | 85 (24.43) | 51 (15.64) | 6 (8.57) | |
Gleason 8-10 | 124 (35.63) | 113 (34.66) | 25 (35.71) | |
Unknown Gleason | 44 (12.64) | 95 (29.14) | 24 (34.29) | |
SIMD 2006, Quintiles | ||||
1 (most deprived) | 117 (33.62) | 128 (39.26) | 27 (38.57) | 0.219 |
2 | 71 (20.40) | 70 (21.47) | 9 (12.86) | |
3 | 46 (13.22) | 45 (13.80) | 9 (12.86) | |
4 | 43 (12.36) | 28 (8.59) | 13 (18.57) | |
5 (least deprived) | 71 (20.40) | 55 (16.87) | 12 (17.14) | |
Prostate specific antigen (ug/l) | ||||
PSA < 10 | 140 (40.35) | 99 (30.46) | 26 (37.14) | <0.001 |
PSA 10-20 | 69 (19.88) | 42 (12.92) | 4 (5.71) | |
PSA > 20 | 138 (39.77) | 184 (56.62) | 40 (57.14) | |
Previous inpatient bed days | ||||
0 | 200 (57.47) | 174 (53.37) | 30 (42.86) | 0.022 |
1-7 | 73 (20.98) | 65 (19.94) | 17 (24.29) | |
8-28 | 55 (15.80) | 64 (19.63) | 11 (15.71) | |
29+ | 20 (5.75) | 23 (7.06) | 12 (17.14) | |